Roblitinib is under clinical development by Everest Medicines and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Roblitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Roblitinib overview
Roblitinib (FGF-401) is under development for the treatment of solid malignancies including hepatocellular carcinoma. The drug candidate is administered orally in the form of capsule. It acts by targeting growth factor receptor-4 (FGFR4).
Everest Medicines overview
Everest Medicines is a biopharmaceutical company. It develops and commercializes pharmaceutical products and vaccines for the treatment of cancer, autoimmune, cardiorenal and infectious diseases. The company’s pipeline products include NEFECON, an oral release formulation that targets mucosal B-cells to treat renal diseases; and EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor to treat renal diseases. Its pipeline also includes Taniborbactam, a novel injectable beta-lactamase inhibitor to treat infectious diseases; and SPR206 for the treatment of MDR gram-negative bacterial infections, among others. Its product includes Xerava, a synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram positive, gram negative and anaerobic pathogens. The company works in collaboration with Immunomedics, Novartis, Arena Pharmaceuticals, and others. Everest Medicines is headquartered in Shanghai, China.
For a complete picture of Roblitinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
